The Role of Maintenance Strategies in Metastatic Colorectal Cancer-Reference-Cited by-同舟云学术

The Role of Maintenance Strategies in Metastatic Colorectal Cancer

Published:2020-03-12 Issue:3 Volume:6 Page:e194489
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Sonbol Mohamad Bassam¹,Mountjoy Luke J.¹,Firwana Belal²,Liu Alex J.¹,Almader-Douglas Diana³,Mody Kabir⁴,Hubbard Joleen⁵,Borad Mitesh¹,Ahn Daniel H.¹,Murad M. Hassan⁶,Bekaii-Saab Tanios¹

Affiliation:

1. Division of Hematology/Oncology, Mayo Clinic, Phoenix, Arizona

2. Heartland Cancer Research NCI Community Oncology Research Program, Missouri Baptist Medical Center, St Louis

3. Mayo Clinic Libraries, Mayo Clinic, Phoenix, Arizona

4. Mayo Clinic Cancer Center, Mayo Clinic, Jacksonville, Florida

5. Mayo Clinic Cancer Center, Mayo Clinic, Rochester, Minnesota

6. Evidence-based Practice Center, Mayo Clinic, Rochester, Minnesota

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2757395/jamaoncology_sonbol_2019_oi_190087.pdf

Reference34 articles.

1. Cancer statistics, 2019.;Siegel;CA Cancer J Clin,2019

2. Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.;Van Cutsem;Ann Oncol,2009

3. Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT.;Hochster;Ann Oncol,2014

4. Treatment decisions in metastatic colorectal cancer—beyond first and second line combination therapies.;Vogel;Cancer Treat Rev,2017

5. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS.;Yoshino;Ann Oncol,2018

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial;The Lancet Gastroenterology & Hepatology;2024-10

2. Intervention of epithelial mesenchymal transition against colon cancer cell growth and metastasis based on SOX21/POU4F2/Hedgehog signaling axis;Life Sciences;2024-09

3. A two-stage maintenance trial of cetuximab-based treatment in RAS and BRAF wild-type unresectable metastatic colorectal cancer: a retrospective real-world study;Frontiers in Oncology;2024-07-23

4. Adverse drug events associated with fluorouracil use in patients with metastatic colorectal cancer: a real-world pharmacovigilance study based on the FDA adverse event reporting system;Expert Opinion on Drug Safety;2024-07-23

5. Gut Microbiota Signatures in Colorectal Cancer as a Potential Diagnostic Biomarker in the Future: A Systematic Review;International Journal of Molecular Sciences;2024-07-20